biotech · Fibrostenotic Crohn’s disease · liver cirrhosis · AGMB
Agomab Therapeutics NV
Agomab Therapeutics NV is a biotech organization headquartered in Tel Aviv, USA. It trades on NYSE under ticker AGMB. Primary therapeutic focus areas include Fibrostenotic Crohn’s disease, liver cirrhosis, Fibrostenotic
Tel Aviv, USA HQ
2011 Founded
20 Employees
Public company Type
AGMB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tel Aviv, USA
- Founded
- 2011
- Employees
- 20
- Programs
- 6
- Drugs
- 2
- Patents
- 4
AGMB-129
Phase 1 · small molecule · Healthy Volunteers
AGMB-129 for Healthy Volunteers is a Phase 1 program (small_molecule) at Agomab Therapeutics NV with 2 ClinicalTrials.gov record(s).
Internal code AGMB-129-C104
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Agomab Therapeutics NV
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Healthy Volunteers
- Status
- completed
- Trials
- 2